Currently, the impact of galectin-3 inhibitors is under investigation in patients with liver fibrosis, but, thus far, the drugs evaluated have not demonstrated efficacy in improving fibrosis [46]. This evidence concerns the gene LGALS3 and Hepatic fibrosis.